Today: 9 June 2026
Blackstone stock steadies in premarket after Trump threatens Wall Street home-buying ban
8 January 2026
1 min read

Blackstone stock steadies in premarket after Trump threatens Wall Street home-buying ban

NEW YORK, Jan 8, 2026, 05:11 EST — Premarket

  • Blackstone shares were flat at $153.59 in premarket trading, after a 5.6% drop on Wednesday.
  • The slide followed President Donald Trump’s pledge to ban large institutional investors from buying more single-family homes.
  • Investors are watching U.S. jobs data on Friday and Blackstone’s quarterly results later this month.

Blackstone Inc shares held steady before the open on Thursday, after a sharp selloff tied to fresh political risk around institutional home buying. The stock last traded at $153.59, unchanged from Wednesday’s close after it fell as low as $147.52 in the session.

Why it matters now: the housing headline hit a corner of the market that had been leaning on lower-rate hopes and a calmer U.S. economy. Blackstone and Apollo Global Management slid more than 5% on Wednesday, weighing on the S&P 500 financials sector.

Trump said his administration was moving to ban Wall Street firms from buying single-family homes and would ask Congress to codify it, though he did not spell out how such a ban would work. “Resident experience is hurting as a result,” said Jeff Holzmann, chief operating officer at RREAF Holdings, a Dallas-based real estate investment firm. Reuters

A 2024 Government Accountability Office report found institutional investors expanded after the 2007-2009 financial crisis, buying foreclosed homes and converting them to rentals, but said data limits make it hard to pin down their effects on tenants and homeownership. The GAO reviewed studies that found investor activity may have lifted rents and prices in some markets.

Blackstone pushed back publicly, saying its ownership of U.S. single-family homes is a small slice of its real estate business and an even smaller part of the overall firm, and that it has been a net seller of homes over the last decade.

The political noise lands ahead of Blackstone’s fourth-quarter and full-year 2025 investor call, scheduled for Jan. 29 at 9:00 a.m. ET. Assets under management — the money it manages for clients — topped $1.2 trillion, the company said in that announcement.

Wall Street will also sift Blackstone’s fee-related earnings, a key measure of recurring management fees stripped of more volatile investment gains. Zacks expects Blackstone to report earnings of $1.52 per share for the quarter.

But the market is still guessing how much of Trump’s plan becomes policy, and how fast. The Associated Press cited an American Enterprise Institute analysis that put institutional investors at about 1% of total single-family housing stock, a reminder that housing supply — not just ownership — drives prices.

Stock Market Today

  • S&P 500 Rallies on Chipmaker Gains; Crude Oil Prices Retreat After Iran-Israel Ceasefire Signal
    June 9, 2026, 9:24 AM EDT. The S&P 500 gained +0.30% on Monday, driven by renewed investor interest in artificial intelligence boosting chipmakers. Nasdaq 100 rose +1.58%, while the Dow slipped -0.16%, dragged lower by Apple's -1% drop amid lukewarm AI platform feedback. Crude oil prices surged over +4% initially due to Iran-Israel tensions but retreated after Iran signaled an end to its current military operation. The market discounts a low 3% chance of a +25 basis point rate hike by the Federal Reserve on June 16-17. Treasury yields climbed, with 10-year notes reaching a two-week high of 4.58%, pressured by strong US jobs data and heavy upcoming Treasury auctions. Overseas markets closed mixed, with China's Shanghai Composite down -1.70% and Japan's Nikkei falling -3.85%.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
City Developments stock climbs after JPMorgan lifts target, flags “strategic review”
Previous Story

City Developments stock climbs after JPMorgan lifts target, flags “strategic review”

Nvidia’s China H200 payment demand hits chip stocks premarket as Intel pops, TSMC sinks
Next Story

Nvidia’s China H200 payment demand hits chip stocks premarket as Intel pops, TSMC sinks

Go toTop